Posaconazole for Coccidioidomycosis

Seventeen of 20 patients with pulmonary or nonmeningeal disseminated coccidioidomycosis responded to posaconazole at 400 mg daily; no severe adverse events were noted.

Coccidioidomycosis is a common problem in the southwestern U.S. and many parts of Latin America. Treatment of severe pulmonary coccidioidomycosis and disseminated infection can be difficult. Posaconazole, a recently approved triazole antifungal, has demonstrated high in vitro activity against Coccidioides immitis. Moreover, in a murine model of coccidioidomycosis, posaconazole was found to be ≥50 times more potent than itraconazole and ≥200 times more potent than fluconazole.

In this manufacturer-funded, multicenter, open-label study, 20 adults with pulmonary or nonmeningeal coccidioidomycosis who had minimal previous antifungal therapy received 400 mg of posaconazole daily for 24 weeks. Seventeen patients (85%) responded to therapy, based o…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Posaconazole for Coccidioidomycosis

Topics

Reviewing Author